Shawn Coffman, MD
Internal Medicine · Huntington, WVNPI 1720022643
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 713 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,830 and has fallen 72.1% since, to $790 in 2025. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 713 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$931
- Novartis$796
- Novo Nordisk$699
- AstraZeneca$675
- Paratek Pharmaceuticals, Inc.$656
- plus $5K from 39 others
What the payments were for
- Food & beverage$9,700100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,706 in reported general payments places this provider in the 95th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 249 | $209,163 |
| XareltoRivaroxaban | 122 | $96,797 |
| JardianceEmpagliflozin | 69 | $95,330 |
| OzempicSemaglutide | 60 | $88,869 |
| TradjentaLinagliptin | 48 | $65,460 |
| TrulicityDulaglutide | 50 | $61,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $52,723 |
| EntrestoSacubitril/Valsartan | 45 | $52,475 |
| RybelsusSemaglutide | 30 | $49,813 |
| JanuviaSitagliptin Phosphate | 31 | $41,024 |
| LinzessLinaclotide | 35 | $39,863 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $31,656 |
| MounjaroTirzepatide | 25 | $31,548 |
| FarxigaDapagliflozin Propanediol | 36 | $31,528 |
| InvokanaCanagliflozin | 14 | $22,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Premarin | $437 | $225,486299 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $313 | $171,300131 claims |
| Novo NordiskOzempic, Rybelsus | $699 | $138,68190 claims |
| Johnson & JohnsonXarelto, Invokana | $591 | $119,636136 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $324 | $93,34675 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $931 | $74,217102 claims |
| NovartisEntresto | $796 | $52,47545 claims |
| AbbVieLinzess, Synthroid | $1,038 | $45,242119 claims |
| AstraZenecaFarxiga, Symbicort | $675 | $41,51960 claims |
| MerckJanuvia | $18 | $41,02431 claims |
| Esperion Therapeutics, Inc.Nexletol | $248 | $6,75217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Huntington
- Bisher MustafaHuntington$28K
- David PatickHuntington$18K
- Stephen SmithHuntington$10K
- Timothy SaxeHuntington$9K
- Maurice MufsonHuntington$4K
- Dawn MacfarlandHuntington$4K
- William ChapmanCharleston$1.7M
- David PickeringParkersburg$599K
- Govind PatelFairmont$59K
- Johny AlencherryMartinsburg$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.